Atlatl Advisers LLC Takes $1.27 Million Position in Axon Enterprise, Inc $AXON

Atlatl Advisers LLC acquired a new stake in Axon Enterprise, Inc (NASDAQ:AXON) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,534 shares of the biotechnology company’s stock, valued at approximately $1,270,000.

Several other large investors have also made changes to their positions in the business. CVA Family Office LLC lifted its position in shares of Axon Enterprise by 26.9% in the second quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 14 shares in the last quarter. LaSalle St. Investment Advisors LLC lifted its position in shares of Axon Enterprise by 2.1% in the first quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 16 shares in the last quarter. Hemington Wealth Management lifted its position in shares of Axon Enterprise by 70.8% in the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 17 shares in the last quarter. Washington Trust Advisors Inc. lifted its position in shares of Axon Enterprise by 44.7% in the second quarter. Washington Trust Advisors Inc. now owns 55 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 17 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in shares of Axon Enterprise by 5.0% in the first quarter. Smartleaf Asset Management LLC now owns 379 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 18 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CFO Brittany Bagley sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the sale, the chief financial officer directly owned 93,592 shares in the company, valued at $66,813,456.96. This represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $713.74, for a total value of $7,137,400.00. Following the sale, the chief executive officer owned 3,033,982 shares in the company, valued at approximately $2,165,474,312.68. This trade represents a 0.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 59,932 shares of company stock valued at $45,115,616. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Trading Up 2.7%

Shares of AXON stock opened at $735.95 on Friday. Axon Enterprise, Inc has a 1 year low of $422.38 and a 1 year high of $885.91. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. The stock’s 50 day simple moving average is $733.17 and its two-hundred day simple moving average is $725.28. The company has a market cap of $57.77 billion, a PE ratio of 181.72, a price-to-earnings-growth ratio of 28.58 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. During the same period in the prior year, the business posted $1.20 earnings per share. The company’s quarterly revenue was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. Research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AXON. Morgan Stanley set a $885.00 target price on Axon Enterprise and gave the stock an “overweight” rating in a report on Friday, July 11th. JPMorgan Chase & Co. lifted their price objective on Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a research note on Thursday, July 17th. Bank of America upped their price objective on Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Piper Sandler began coverage on Axon Enterprise in a research report on Tuesday, September 23rd. They set an “overweight” rating and a $893.00 target price for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $870.00 price target on shares of Axon Enterprise in a research report on Wednesday, September 24th. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus target price of $841.64.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.